The evaluation of celecoxib against skin toxicity caused by radiotherapy in patients with breast cancer

Phase 2

• Conditions: Radiodermatitis.; Malignant neoplasm of breast, Acute radiodermatitis; C50, L58

• Registration Number: IRCT2014100619423N1
• Lead Sponsor: Vice Chancellor for Research and Technology, Mazandaranl University of Medical Scenices

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Inclusion criteria; Adults over 18 years and less 70 years; breast cancer;about 50Gy total dose of radiation.Exclusion criteria:Smoking; sing the anti-inflammatory drug such as dexametasone and NSAID, active skin infection and dermatitis; using any topical products on breast; the disease weakens related to the immune system and a lack of diabetes that affected on wound healing; diseases related to kidney and liver.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of radiation-induced skin toxicity (such as Erythema, dry desquamation, itching, and ulcer). Timepoint: Just before drug treatment and then weekly for end of radiotehrapy. Method of measurement: According to RTOG scoring system with a questionnair.